Free cash flow remains highly volatile, swinging from a 31.0% margin in 2025Q1 to a negative 4.4% in 2024Q4, highlighting the difficulty in achieving stable cash generation.
| Cash from Operations | 39.27M | 53.78M | 58.2M | 41.19M | 35.58M | 25.21M | 23.22M | 21.59M |
| Operating CF Margin % | - | 22.27% | 23.08% | 16.38% | 15.98% | 15.17% | 19.62% | 25.26% |
| Operating CF Growth % | -175.2% | -7.59% | 41.29% | 15.77% | 41.12% | 8.59% | 7.52% | - |
| Net Income | -170.32M | -199.3M | -591.45M | -202.39M | -22.25M | -62.32M | -52.6M | -36.4M |
| Depreciation & Amortization | 55.54M | 56.11M | 51.67M | 51.75M | 56.9M | 59.95M | 59.58M | 33.54M |
| Stock-Based Compensation | 27.05M | 29.14M | 38.09M | 48.74M | 36.43M | 9.96M | 1.75M | 0 |
| Deferred Taxes | 24.4M | -10.88M | -119.58M | -18.71M | -26.67M | -587K | 0 | 0 |
| Other Non-Cash Items | 141.16M | 188.12M | 705.4M | 192.19M | 13.12M | 20.73M | 14.63M | 12.02M |
| Working Capital Changes | -26.04M | -9.42M | -25.93M | -30.39M | -21.95M | -2.51M | -147K | 12.43M |
| Change in Receivables | 4.29M | 1.38M | 5.69M | 811K | -13.22M | -10.73M | -8.29M | -8.62M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -3.92M | -1.09M | -5.46M | 1.33M | 358K | 3.42M | 4.44M | 7.95M |
| Cash from Investing | 64.11M | 153.88M | -26.41M | -31.78M | -248.9M | -46.73M | -23.86M | -1.14B |
| Capital Expenditures | -2.22M | -16.72M | -12.34M | -2.98M | -8.33M | -6.73M | -1.4M | -1.9M |
| CapEx % of Revenue | 0.93% | 6.92% | 4.89% | 1.18% | 3.74% | 4.05% | 1.18% | 2.22% |
| Acquisitions | 0 | 0 | -13.53M | -45.02M | -56.3M | -40M | -22.47M | -1.14B |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | -10M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | -51.96M | -150.79M | -56.75M | -25.58M | -26.7M | 384.37M | 16.66M | 1.12B |
| Debt Issued (Net) | -8.75M | -79.47M | -13.75M | -8.59M | -6.88M | -199.46M | 13.46M | 434.62M |
| Equity Issued (Net) | -28.3M | -49.45M | -22.37M | -30K | -1.73M | 603.18M | 0 | 696.99M |
| Dividends Paid | -3.15M | -3.15M | -5.13M | -12.28M | -12.87M | -8.13M | -2.94M | -6.96M |
| Share Repurchases | -28.3M | -49.45M | -22.37M | 0 | 0 | -231.77M | 0 | 0 |
| Other Financing | -11.76M | -18.71M | -15.5M | -4.68M | -5.22M | -11.22M | 6.14M | 0 |
| Net Change in Cash | 51.55M | 58.25M | -25.6M | -15.96M | -240.56M | 362.72M | 16.16M | 8.62M |
| Free Cash Flow | 37.06M | 37.06M | 45.85M | 38.21M | 27.25M | 18.48M | 21.82M | 19.69M |
| FCF Margin % | 15.55% | 15.34% | 18.18% | 15.2% | 12.24% | 11.12% | 18.44% | 23.03% |
| FCF Growth % | -22.62% | -19.18% | 19.99% | 40.22% | 47.47% | -15.31% | 10.81% | - |
| FCF per Share | 0.35 | 0.35 | 0.39 | 0.34 | 0.27 | 0.19 | 0.22 | 0.13 |
| FCF Conversion (FCF/Net Income) | -0.22x | -0.39x | -0.14x | -0.20x | -4.93x | -0.49x | -0.44x | -0.59x |
| Interest Paid | 2.87M | 0 | 0 | 14.46M | 0 | 29.57M | 25.96M | 0 |
| Taxes Paid | 176K | 0 | 0 | 136K | 0 | 13K | 0 | 0 |
Persistent Revenue Contraction
As reported in recent financial filings, Definitive Healthcare exhibits a persistent disconnect between net income and operating cash flow, with the company consistently reporting negative net income while maintaining positive operating cash flow, a trend that warrants careful scrutiny regarding the sustainability of its underlying business model.
The consistent gap between GAAP net losses and positive operating cash flow suggests that non-cash charges, particularly stock-based compensation and amortization, are significantly distorting the company's reported profitability. Investors should monitor whether this cash generation is truly operational or if it relies on aggressive working capital management that may not be repeatable in future periods.
Based on the provided quarterly data, Definitive Healthcare's free cash flow trajectory remains highly erratic, with margins swinging from a high of 31.0% in 2025Q1 to a negative 4.4% in 2024Q4, indicating that the company has yet to establish a predictable or stable cash generation profile.
This volatility appears to be driven by lumpy capital expenditures and shifting working capital requirements rather than a steady operational cadence. The inability to maintain positive free cash flow consistently suggests that the business model remains in a transition phase where growth investments frequently overwhelm core cash generation capabilities.
According to historical cash flow statements, Definitive Healthcare's capital expenditure patterns have fluctuated significantly, with CapEx as a percentage of revenue spiking to 17.5% in 2024Q4, which may indicate periodic, non-linear investments in data infrastructure rather than a steady-state maintenance requirement for the platform.
The variability in capital intensity suggests that the company's data-as-a-service model requires periodic, heavy reinvestment to keep its proprietary datasets relevant. Analysts should investigate whether these spikes represent necessary upgrades to maintain the competitive moat or if they reflect inefficient capital allocation during periods of revenue contraction.
As evidenced by the quarterly cash flow data, working capital changes have frequently acted as a drag on cash flow, with significant outflows such as the $15.7 million reduction in 2024Q4, suggesting potential challenges in managing receivables or timing of payments relative to the company's subscription-based revenue model.
The inconsistent impact of working capital on cash flow may imply that the company is struggling to align its cash collection cycle with its revenue recognition. This lack of synchronization warrants further investigation into whether the firm is offering extended payment terms to retain clients amidst the current revenue contraction.
Based on reported figures, Definitive Healthcare has prioritized share repurchases despite its negative net income, with significant outflows observed in 2025, a strategy that appears aggressive given the company's current struggle to achieve consistent top-line growth and GAAP profitability in a challenging healthcare information services market.
The decision to return capital to shareholders while the core business is contracting suggests a management focus on supporting the stock price rather than reinvesting in organic growth or debt reduction. This capital allocation strategy may limit the company's financial flexibility should the current revenue headwinds persist or intensify.
Quick answers to the most common questions about buying DH stock.
Definitive Healthcare Corp. (DH) generated $53.8M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Definitive Healthcare Corp. (DH) generated $37.1M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Definitive Healthcare Corp. (DH) spent $16.7M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, Definitive Healthcare Corp. (DH) returned $3.1M to shareholders via cash dividends and spent $49.5M on share repurchases. This shows the company's commitment to returning capital to its equity investors.